Last reviewed · How we verify
NCT05987605
Phase I/II Clinical Study of 1A46 Drug Substance
Phase 1 trial testing 1A46 Drug Substance in Advanced Malignancies in 4 participants. Terminated before completion.
20 August 2024
Quick facts
| Lead sponsor | BioRay Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | other |
| Enrollment | 4 |
| Start date | 12 September 2023 |
| Primary completion | 20 August 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 1A46 Drug Substance — full drug profile →
Conditions studied
- Advanced Malignancies — all drugs for Advanced Malignancies →
Sponsor
BioRay Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell non-Hodgkin's lymphoma (B - NHL)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
Verify or expand the search:
- PubMed search for NCT05987605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignancies
Currently open trials in the same condition.
- NCT06937957 — A Study of BR111 in Patients With Advanced Malignancies · Phase 1 · recruiting
- NCT06401356 — An Extension Study for Patients Previously Enrolled in Studies With Pelabresib · Phase 3 · recruiting
- NCT06468098 — A Study of IBI363 in Subjects With Advanced Malignancies · Phase 1 · recruiting
- NCT06717880 — A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer · Phase 1 · recruiting
- NCT05059522 — Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing · Phase 3 · active not recruiting
Other BioRay Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07498647 — Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia · Phase 2 · not yet recruiting
- NCT06937957 — A Study of BR111 in Patients With Advanced Malignancies · Phase 1 · recruiting
- NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
- NCT06289894 — A Study of BRY805 in Participants With Advanced Solid Tumors · Phase 1 · terminated
- NCT06126718 — Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05987605 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioRay Pharmaceutical Co., Ltd.
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05987605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing